|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-10-8
|
|
pubmed:abstractText |
The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) was modified for use in mild cognitive impairment (MCI) trials and tested in the ADCS MCI randomized clinical trial of donepezil, vitamin E, and placebo. We assessed feasibility for its use by determining whether or not: (1) it distinguished a medication effect at 6 months and 12 months, (2) baseline demographic or clinical characteristics predicted change, (3) there was an association between MCI-CGIC and change in other clinical measures in order to evaluate external or concurrent validity.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-10599762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-1202204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-14732621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-15326237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-15829527,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-17135811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-17287448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-7114305,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-8232972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-8970010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-8994890,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19812469-9236948
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1546-4156
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
260-7
|
|
pubmed:dateRevised |
2010-9-27
|
|
pubmed:meshHeading |
pubmed-meshheading:19812469-Activities of Daily Living,
pubmed-meshheading:19812469-Alzheimer Disease,
pubmed-meshheading:19812469-Antioxidants,
pubmed-meshheading:19812469-Cholinesterase Inhibitors,
pubmed-meshheading:19812469-Cognition Disorders,
pubmed-meshheading:19812469-Disease Progression,
pubmed-meshheading:19812469-Humans,
pubmed-meshheading:19812469-Indans,
pubmed-meshheading:19812469-Memory,
pubmed-meshheading:19812469-Neuropsychological Tests,
pubmed-meshheading:19812469-Piperidines,
pubmed-meshheading:19812469-Randomized Controlled Trials as Topic,
pubmed-meshheading:19812469-Severity of Illness Index,
pubmed-meshheading:19812469-Vitamin E
|
|
pubmed:articleTitle |
Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.
|
|
pubmed:affiliation |
Departments of Psychiatry and Neurology, Keck School of Medicine, University of Southern California, 1510 San Pablo Street, Los Angeles, CA 90033, USA. lschneid@usc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
